Cellmark Diagnostics (UK) and Lifecodes (US) sign joint agreement:
This article was originally published in Clinica
Cellmark Diagnostics (UK) and Lifecodes (US) have signed a joint manufacturing and distribution agreement covering their forensic and paternity testing DNA tests. Under the agreement Cellmark will manufacture Lifecodes DNA profiling probes in its non-isotopic enhanced chemiluminescence format. From July 1st Cellmark will distribute Lifecodes probes throughout Europe and 15 other countries. In the US both companies will sell each others' forensic products, while Lifecodes will exclusively market both ranges of paternity kits.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.